UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view

British journal of haematology, 2011-06, Vol.153 (6), p.709-720

2011

Link zum Volltext

Verfügbarkeit prüfen

Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm

Annals of hematology, 2020-04, Vol.99 (4), p.907-909

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06

Haematologica (Roma), 2020-08, Vol.106 (10), p.2578-2587

2020

Link zum Volltext

Verfügbarkeit prüfen

Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria

International journal of hematology, 2006-08, Vol.84 (2), p.104-112

2006

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience

Journal of clinical medicine, 2021-04, Vol.10 (8), p.1684

2021

Link zum Volltext

Verfügbarkeit prüfen

Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category

Cancers, 2020-11, Vol.12 (11), p.3196

2020

Link zum Volltext

Verfügbarkeit prüfen

Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia

Haematologica (Roma), 2010-05, Vol.95 (5), p.833

2010

Link zum Volltext

Verfügbarkeit prüfen

Peripheral blood blast clearance during induction therapy in acute myeloid leukemia

Blood, 2008-02, Vol.111 (3), p.1746-1747

2008

Link zum Volltext

Verfügbarkeit prüfen

CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia

Cytometry. Part B, Clinical cytometry, 2014-09, Vol.86 (5), p.340-349

2014

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

Blood, 2022-11, Vol.140 (Supplement 1), p.9008-9009

2022

Link zum Volltext

Verfügbarkeit prüfen

ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S242-S243

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S159-S159

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S154-S154

2023

Link zum Volltext

Verfügbarkeit prüfen

AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S285-S286

2023

Link zum Volltext

Verfügbarkeit prüfen

Focal spleen lesions in visceral leishmaniasis, a neglected manifestation of a neglected disease: report of three cases and systematic review of literature

Infection, 2019-08, Vol.47 (4), p.507-518

2019

Link zum Volltext

Verfügbarkeit prüfen

POSTER: AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S158-S158

2023

Link zum Volltext

Verfügbarkeit prüfen

AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S281-S282

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(58)
Berichte
(1)

Sprache

Englisch
(59)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Humans
(22)
Hematology
(21)
Female
(17)
Male
(17)
Middle Aged
(17)
Adult
(16)
Aged
(15)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Acute Myeloid Leukemia
(10)
Hematologic And Hematopoietic Diseases
(10)
Young Adult
(10)
Adolescent
(8)
Prognosis
(8)
Treatment Outcome
(7)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(6)
Flow Cytometry
(5)
Anemias. Hemoglobinopathies
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06

Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience

Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category

High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program

P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia

High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG)

CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease

Peripheral blood blast clearance during induction therapy in acute myeloid leukemia

CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia

ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting

POSTER: AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting

POSTER: ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting

AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting

CEBPA -double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features

Focal spleen lesions in visceral leishmaniasis, a neglected manifestation of a neglected disease: report of three cases and systematic review of literature

POSTER: AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications

AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications

Suchergebnisse filtern